N/A N=1,676 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA
Venous Thromboembolism
Primary: Occurrence of Symptomatic Venous Thromboembolic Events — 19; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Neuroblastoma
Primary: Number of Responders (Response Rate) — 0; 5; 13; 18 participants
Phase 1 N=18 The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers
High Altitude Pulmonary Hypertension
Primary: Mean Number of Adverse Events Following Each Dose — 2.5; 0.4; 0.8; 0.4 Mean number of adverse events
N/A N=8 Transfusions and Nitric Oxide Level in Preterm Infants
Prematurity · Anemia · Necrotizing Enterocolitis
Primary: SNOHgB Levels
Phase 3 N=18 Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants
Gastroesophageal Reflux
Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day
Phase 4 N=120 A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
Influenza, Human
Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 79; 79; 64.7 percentage of participants
Phase 2 N=63 Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
Colorectal Cancer
Primary: Median Time for Progression Free Survival — 15.8 Months
Phase 2 N=50 N-Acetyl Cysteine in Trichotillomania
Trichotillomania
Primary: Massachusetts General Hospital Hairpulling Scale — 17.6; 16.7; 10.4; 16.0 units on a scale
Phase 3 N=340 A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
Pain
Primary: Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical…
N/A N=100 Rapid, Minimally-invasive Voluntary Adult Male Circumcision
Circumcision
Primary: Intraoperative Duration — 9.0; 22.6 Min
Phase 3 N=299 Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial
Parkinson's Disease
Primary: The Change From Baseline in the UPDRS-III Score at 24 Months With Deep-brain Stimulation and Without Medication. — -12.9; -13.1 units on a scale
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 4 N=120 A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
Influenza, Human
Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 72.9; 63.3; 78.0; 55.0 percentage of participants
N/A N=46 Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Hyperglycemia · Hyperlipidemia
Primary: Whole Body Insulin Sensitivity — 4.9; 5.4; 4.1; 2.9 mg/kg/min — p=0.001
Phase 3 N=263 TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Lipodystrophy · HIV Infections
Primary: Changes From Baseline in Fasting Blood Glucose at Week 52 — 0; -2; 1 mg/dL — p=>0.05